Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke

Przemysław Węglarz; Michał Węgiel; Ewa Konarska-Kuszewska; Piotr Kuszewski; Michał Staszel; Artur Dziewierz; Tomasz Rakowski

doi:10.5114/aic.2023.131479

eISSN: 1897-4295
ISSN: 1734-9338

Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2023
vol. 19

Send email

Copy url:

abstract:

Original paper

Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke

Przemysław Węglarz

^{1, 2}

,

Michał Węgiel

³

,

Ewa Konarska-Kuszewska

^{1, 2}

,

Piotr Kuszewski

⁴

,

Michał Staszel

²

,

Artur Dziewierz

^{3, 5}

,

Tomasz Rakowski

^{3, 5}

Center for Invasive Cardiology, Electrotherapy and Angiology, Oświęcim, Poland
Department of Cardiology, Tytus Chałubiński Hospital, Zakopane, Poland
Clinical Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland
Department of Cardiology, Municipal Hospital No. 4, Gliwice, Poland
2nd Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

Adv Interv Cardiol 2023; 19, 3 (73): 257–261

DOI: https://doi.org/10.5114/aic.2023.131479

Online publish date: 2023/09/27

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Węglarz P, Węgiel M, Konarska-Kuszewska E, et al. Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2023;19(3):257-261. doi:10.5114/aic.2023.131479.

APA

Węglarz, P., Węgiel, M., Konarska-Kuszewska, E., Kuszewski, P., Staszel, M.,  & Dziewierz, A. et al. (2023). Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 19(3), 257-261. https://doi.org/10.5114/aic.2023.131479

Chicago

Węglarz, Przemysław, Michał Węgiel, Ewa Konarska-Kuszewska, Piotr Kuszewski, Michał Staszel, Artur Dziewierz,  and Tomasz Rakowski. 2023. "Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej 19 (3): 257-261. doi:10.5114/aic.2023.131479.

Harvard

Węglarz, P., Węgiel, M., Konarska-Kuszewska, E., Kuszewski, P., Staszel, M., Dziewierz, A.,  and Rakowski, T. (2023). Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 19(3), pp.257-261. https://doi.org/10.5114/aic.2023.131479

MLA

Węglarz, Przemysław et al. "Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, vol. 19, no. 3, 2023, pp. 257-261. doi:10.5114/aic.2023.131479.

Vancouver

Węglarz P, Węgiel M, Konarska-Kuszewska E, Kuszewski P, Staszel M, Dziewierz A et al. Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2023;19(3):257-261. doi:10.5114/aic.2023.131479.

Introduction:
Nowadays, percutaneous closure of patent foramen ovale (PFO) in patients after cryptogenic stroke is becoming a dominating strategy. The most commonly used and investigated device is the Amplatzer occluder. However, several other devices have been designed for transcatheter closure of PFO, which are not so well examined.

Aim:
To assess the effectiveness and safety of PFO closure with the Lifetech CERA occluder.

Material and methods:
A prospective, single-arm registry of patients with PFO treated with CERA occluder (Lifetech Scientific, Shenzhen, China) implantation was conducted. We assessed peri-procedural and 12-month follow-up. Patients were screened for the residual shunt in transcranial Doppler/transesophageal echocardiography.

Results:
Ninety-six patients entered the registry. Most patients were women (76%) and the analyzed group was relatively young (mean age of 42.3 ±13.6 years). Before closure, most patients had a large shunt through the PFO. Procedures of PFO closure were performed under TEE guidance. All procedures were made under local anesthesia and all patients had the PFO successfully closed. No device-related complications were reported in the peri-procedural period or during follow-up. No recurrent neurological ischemic events were reported at 12 months. During follow-up we observed a 9% rate of residual shunts, which were mostly small.

Conclusions:
The study confirmed excellent immediate and 12-month results of CERA occluder implantation in patients with PFO.

keywords:

Experience in patent foramen ovale closure with the CERA Lifetech occluder in patients with cryptogenic stroke

Przemysław Węglarz 1, 2 , Michał Węgiel 3 , Ewa Konarska-Kuszewska 1, 2 , Piotr Kuszewski 4 , Michał Staszel 2 , Artur Dziewierz 3, 5 , Tomasz Rakowski 3, 5

atrial septum, Amplatzer occluder device, prevention, follow-up study

Przemysław Węglarz

^{1, 2}

,

Michał Węgiel

³

,

Ewa Konarska-Kuszewska

^{1, 2}

,

Piotr Kuszewski

⁴

,

Michał Staszel

²

,

Artur Dziewierz

^{3, 5}

,

Tomasz Rakowski

^{3, 5}